Improved Alzheimer's disease versus frontotemporal lobar degeneration differential diagnosis combining EEG and neurochemical biomarkers: A pilot study

Manuscript Number: 

22-0693R1

Author(s): 
Maria Bjerke, Peter Paul De Deyn, Maarten De Vos, Sebastiaan Engelborghs, Johan Goeman, Joery Goossens, Jorne Laton, Jean-Jacques Martin, Guy Nagels, Anne Sieben, Johannes Streffer, Christine Van Broeckhoven, Jeroen Van Schependom, Wietse Wiels, Julie van der Zee

Disclosures

Maria Bjerke

  • Nothing to Disclose

Peter Paul De Deyn

  • Nothing to Disclose

Maarten De Vos

  • Nothing to Disclose

Sebastiaan Engelborghs

  • Consulting Fees:
    Biogen, Danone, Eisai, icometrix, Novartis, Nutricia, and Roche
    Grants
    • Agency: 
      Janssen Pharmaceutica and ADx Neurosciences (outside submitted work)
      Dates: 
      1 SEP 2016 - 31 DEC 2022

Johan Goeman

  • Nothing to Disclose

Joery Goossens

  • Nothing to Disclose

Jorne Laton

  • Nothing to Disclose

Jean-Jacques Martin

  • Nothing to Disclose

Guy Nagels

  • Consulting Fees:
    Advisory boards on multiple sclerosis.
    Equity:
    Minority shareholder in icometrix nv
    Lecture Fees:
    Lectures for Novartis, Roche, Merck, BMS on multiple sclerosis and on data science

Anne Sieben

  • Nothing to Disclose

Johannes Streffer

  • Nothing to Disclose

Christine Van Broeckhoven

  • Nothing to Disclose

Julie van der Zee

  • Nothing to Disclose

Jeroen Van Schependom

  • Nothing to Disclose

Wietse Wiels

  • Nothing to Disclose